ClinicalTrials.gg
CompletedNCT05593250Updated Oct 15, 2026

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

A Phase 2 interventional study of SHR-1905 and placebo in Asthma, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
3rd of 15
260 · median 84
Started
2023
the only one that year
Phase 2
6 of 15
3 open now
Registered
8th of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 6 in phase 2, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study is a phase 2 study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged between 18 and 75 years (inclusive)
  2. Weight ≥ 40 kg
  3. Meet the diagnostic criteria for asthma and have a medical history of at least 1 year
  4. Treatment with a total daily dose of either medium or high dose inhaled (ICS) for at least 6 months before screening, with a stable use for 3 months before randomization
  5. At least one additional maintenance asthma controller with stable use for at least 3 months before randomization
  6. At least 2 exacerbations within 12 months before screening
  7. No birth plan and must agree to take effective methods
  8. Sign form voluntarily for the trial

Exclusion criteria

Exclusion Criteria:

  1. Any pulmonary disease
  2. Any disease other than asthma that may affect lung function
  3. Any disease other than asthma related to elevation of eosinophils
  4. Any immunodeficiency disease
  5. Any clinically important serious cardiovascular diseases unstable or uncontrolled
  6. Uncontrolled Hypertension
  7. Uncontrolled Diabetes Mellitus
  8. Any clinically important infections within 4 weeks before randomization
  9. Any major surgery within 3 months before randomized, or any surgical plan during the study, or any treatment that may affect the evaluation of the subjects considered by the investigator
  10. Any parasitic infections within 6 months before randomization
  11. diagnosed within 5 years before randomization
  12. Abnormal laboratory tests during screening and baseline
  13. Positive infectious disease test
  14. Prolonged or other clinical significant abnormal findings in at screening that may cause safety risk to the subject
  15. Current smoker or smoking cessation for less than 6 months at screening, or smoking history ≥10 pack- years
  16. Drug or alcohol abuse
  17. Allergy history to any biologicsl or other agent that investigator think the subject should not participate in the study
  18. Subjects who are pregnant or breastfeeding, or plan to become pregnant during the study
  19. Participated in other clinical trials and used drugs containing active ingredients within 4 weeks or 5 half-lives before screening
  20. Any other circumstance inappropriate for participating in the clinical trial considered by the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Cohort A

    dose 1

    Drug: SHR-1905

  • Experimental
    Cohort B

    dose 2

    Drug: SHR-1905

  • Experimental
    Cohort C

    dose 3

    Drug: SHR-1905

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • subcutaneous

  • Drugplacebo

    subcutaneous ,placebo

06

What researchers measure

Primary outcomes

  1. Efficacy:Annual asthma exacerbation rate (AAER)

    Time frame: From randomisation to 48 weeks

Secondary outcomes

  1. Changes of fractional exhaled nitric oxide (FeNO) compared with baseline

    Time frame: Baseline to72 weeks

  2. Changes from baseline in Asthma Control questionnaire (ACQ-6) scores

    Time frame: Baseline to 72 weeks

  3. Changes from baseline in Asthmatic Quality of Life Questionnaire (AQLQ) scores

    Time frame: Baseline to 72 weeks

  4. AAER associated with hospitalization at 48 weeks

    Time frame: From randomisation to 48 weeks

  5. Changes from baseline in Asthma Symptom Diary scores

    Time frame: Baseline to 72 weeks

  6. The proportion of subjects with acute exacerbations of asthma

    Time frame: Baseline to 72 weeks

  7. Changes from baseline in weekly reliever use

    Time frame: Baseline to 72 weeks

  8. Changes from baseline in weekly mean morning and evening peak expiratory flow (PEF)

    Time frame: Baseline to 72 weeks

  9. Changes from baseline in weekly mean number of night time awakenings

    Time frame: Baseline to 72 weeks

  10. Time to the first acute asthma exacerbation

    Time frame: Baseline to 72 weeks

  11. The proportion of subjects with composite endpoint for asthma (CompEx)

    Time frame: Baseline to72 weeks

  12. Pharmacokinetics (PK): Serum concentration of SHR-1905

    Time frame: 72 weeks

07

Study locations

1 site
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510163, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2025, 34 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 34 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2026 → Dec 2025 and completion Dec 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 25, 2022
StartActual
Jan 17, 2023
Primary completionActual
Dec 5, 2025was Dec 2026
CompletionActual
May 21, 2026was Dec 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Primary completion
Dec 30, 2026→Dec 5, 2025 (actual)
Oct 15, 2026
Study completion
Dec 30, 2026→May 21, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    Primary completion Dec 30, 2026→Dec 5, 2025 (now actual)
    Study completion Dec 30, 2026→May 21, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05593250
Responsible party
Sponsor
First posted
Oct 25, 2022
Start date
Jan 17, 2023
Primary completion
Dec 5, 2025
Completion
May 21, 2026
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1905

Start the discussion